Eisai Sustainability Profile
Eisai Co., Ltd., commonly referred to as Eisai, is a prominent global pharmaceutical company headquartered in Japan. Established in 1941, Eisai has made significant strides in the healthcare industry, focusing on the discovery, development, and marketing of innovative medicines. With major operational regions across Asia, Europe, and North America, the company is dedicated to addressing unmet medical needs, particularly in neurology and oncology. Eisai's core products include treatments for Alzheimer's disease and various cancers, distinguished by their commitment to patient-centric solutions. The company has achieved notable recognition for its research and development efforts, positioning itself as a leader in the pharmaceutical sector. With a strong emphasis on ethical practices and collaboration, Eisai continues to enhance its market presence while striving to improve the quality of life for patients worldwide.
DitchCarbon Score
How does Eisai's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eisai's score of 59 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eisai's reported carbon emissions
In 2023, Eisai Co., Ltd., headquartered in Japan, reported total greenhouse gas emissions of approximately 48586000 kg CO2e for Scope 1, 2673000 kg CO2e for Scope 2, and a significant 563928000 kg CO2e for Scope 3 emissions. This reflects a commitment to transparency in their emissions reporting across all scopes. Eisai has set ambitious reduction targets, aiming to decrease Scope 1 and Scope 2 emissions by 55% by fiscal 2030 from a 2019 baseline. Additionally, they plan to reduce Scope 3 emissions from purchased goods and services by 27.5% within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are classified under the 1.5°C pathway, indicating a strong commitment to climate action. The company has also pledged to achieve net-zero emissions by 2050, further demonstrating its dedication to sustainability and climate responsibility. These initiatives are crucial in the pharmaceutical sector, where emissions reduction is increasingly vital for corporate accountability and environmental stewardship.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 49,457,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,830,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 456,386,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Eisai's Industry?
How Carbon Intensive is Eisai's Location?
Eisai's Scope 3 Categories Breakdown
Eisai's Scope 3 emissions, which decreased by 6% last year and increased by approximately 24% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" representing nearly all of their reported Scope 3 footprint.
Top Scope 3 Categories
Eisai's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Eisai has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Teva Branded Pharmaceutical Products R&D, Inc.
Frequently Asked Questions
Common questions about Eisai's sustainability data and climate commitments